Can-Fite BioPharma Ltd. CANF
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 405.00K | 405.00K | 405.00K | 482.50K | 560.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 405.00K | 405.00K | 405.00K | 482.50K | 560.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 405.00K | 405.00K | 405.00K | 482.50K | 560.00K |
| SG&A Expenses | 3.02M | 3.34M | 3.66M | 3.63M | 3.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.14M | 10.25M | 10.36M | 9.92M | 9.49M |
| Operating Income | -9.73M | -9.84M | -9.95M | -9.44M | -8.93M |
| Income Before Tax | -9.55M | -9.69M | -9.83M | -9.31M | -8.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.55 | -9.69 | -9.83 | -9.31 | -8.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.55M | -9.69M | -9.83M | -9.31M | -8.80M |
| EBIT | -9.73M | -9.84M | -9.95M | -9.44M | -8.93M |
| EBITDA | -9.73M | -9.83M | -9.93M | -9.42M | -8.91M |
| EPS Basic | -3.54 | -5.06 | -6.59 | -7.76 | -8.94 |
| Normalized Basic EPS | -2.21 | -3.16 | -4.11 | -4.85 | -5.58 |
| EPS Diluted | -3.54 | -5.06 | -6.59 | -7.76 | -8.94 |
| Normalized Diluted EPS | -2.21 | -3.16 | -4.11 | -4.85 | -5.58 |
| Average Basic Shares Outstanding | 11.73M | 9.16M | 6.58M | 5.27M | 3.96M |
| Average Diluted Shares Outstanding | 11.73M | 9.16M | 6.58M | 5.27M | 3.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |